Site icon pharmaceutical daily

Cystic Fibrosis (CF) Pipeline Insight Report 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cystic Fibrosis (CF) – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This Cystic Fibrosis (CF) – Pipeline Insight, 2020, report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cystic Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cystic Fibrosis Emerging Drugs Chapters

This segment of the Cystic Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cystic Fibrosis Emerging Drugs

MRT5005: Translate Bio

MRT5005 is the first clinical-stage mRNA product candidate designed to address the underlying cause of CF by delivering mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to the lung epithelial cells through nebulization. MRT5005 is being developed to treat all patients with CF, regardless of the underlying genetic mutation, including those with limited or no CFTR protein. This mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020.

Cystic Fibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:

(Read more…)

Major Players in Cystic Fibrosis

There are approx. 50+ key companies which are developing the therapies for Cystic Fibrosis. The companies which have their Cystic Fibrosis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, SolAeroMed Inc., Eloxx Pharmaceuticals, Inc., Corbus Pharmaceuticals Inc., Laurent Pharmaceuticals Inc. etc.

Phases

This report covers around 50+ products under different phases of clinical development like

Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Products have been categorized under various Molecule types such as

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cystic Fibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystic Fibrosis drugs.

Report Highlights

Cystic Fibrosis Report Insights

Cystic Fibrosis Report Assessment

Key Questions

Current Treatment Scenario and Emerging Therapies:

Key Players

Key Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6kml8p

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version